Skip to main content
MediWound Ltd. logo

MediWound Ltd. — Investor Relations & Filings

Ticker · MDWD ISIN · IL0011316309 LEI · 549300LJKCS74GRYKF90 US Manufacturing
Open in API
Filings indexed 370 across all filing types
Latest filing 2023-05-30 Regulatory Filings
Country IL Israel
Listing US MDWD

About MediWound Ltd.

https://www.mediwound.com/

MediWound Ltd. is a fully integrated biopharmaceutical company that develops, manufactures, and commercializes enzymatic therapeutics for non-surgical tissue repair. The company's core technology focuses on next-generation treatments that selectively remove eschar (non-viable tissue) from severe burns and chronic wounds while preserving healthy tissue. This approach is designed to accelerate healing, improve patient outcomes, and lower overall healthcare costs. Its primary commercial product is a topical biologic for the debridement of severe thermal burns. MediWound maintains a research and development pipeline aimed at expanding its enzymatic platform to address additional unmet medical needs in wound care.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release titled 'MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update' as Exhibit 99.1. The document length is 2454 characters, which is relatively short and mainly serves to announce the press release rather than containing detailed financial statements or analysis itself. According to the 'Menu vs Meal' rule, short documents that announce or attach reports should be classified as Regulatory Filings (RNS) rather than the report type they reference. Therefore, this document is best classified as a Regulatory Filing (RNS).
2023-05-30 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release about an additional $10 million award from BARDA. The document is relatively short (2341 characters) and primarily serves to announce this press release. There are no financial statements or detailed financial data included. The document does not contain an annual report, interim report, or detailed management discussion. It is not a certification or officer attestation. The document is essentially a regulatory announcement of a press release, fitting best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-05-09 English
6-K
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, MediWound Ltd., containing proxy materials for the upcoming 2023 Annual General Meeting (AGM). It includes a Notice of Annual General Meeting and Proxy Statement, as well as a Proxy Card. The document is short (2959 characters) and primarily serves to distribute proxy materials related to the AGM. The content is not the AGM presentation itself but the proxy solicitation materials. According to the filing definitions, proxy solicitation materials are classified under Proxy Solicitation & Information Statement (PSI).
2023-04-20 English
424B3
Capital/Financing Update Classification · 100% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) under the Securities Act, related to the resale of ordinary shares by selling shareholders. It details the offering of shares, warrants, and related securities, including descriptions of the securities, risk factors, use of proceeds, plan of distribution, and legal matters. The document is a registration statement prospectus for a securities offering, not a financial report, earnings release, or management discussion. It is a capital markets document related to financing activities and share issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a report publication announcement but a full prospectus related to capital raising and share resale.
2023-04-06 English
Regulatory Filings 2023
Regulatory Filings
2023-04-06 English
POS AM
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to a Form F-1 registration statement filed with the SEC, converting the registration statement on Form F-1 into a Form F-3. It relates to the registration of securities for resale by selling shareholders and includes detailed information about the offering, selling shareholders, and related legal and financial disclosures. This is a regulatory filing related to securities registration and offering, not a financial report, earnings release, or management discussion. It is a formal SEC filing concerning capital markets activities, specifically a registration statement amendment. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2023-03-31 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.